UK Markets closed

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
2.7170-0.0210 (-0.77%)
At close: 05:41PM BST
Full screen
Previous close2.7380
Open2.7660
Bid2.6500 x 0
Ask2.7840 x 0
Day's range2.7120 - 2.7660
52-week range2.1916 - 10.7900
Volume3,627
Avg. volume8,798
Market cap149.39M
Beta (5Y monthly)2.04
PE ratio (TTM)N/A
EPS (TTM)-1.9930
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights04/30/202255,095,537 Total gross of voting rights: 55,095,537 Total net* of voting rights: 54,920,329 * Total net = total number of voting rights attached to shares – shares witho

  • Globe Newswire

    DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

    Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies. The Company’s shareholders approved all resolutions submitted b

  • Globe Newswire

    DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

    Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, today announced that, pursuant to the Company’s At-The-Market program established on May 2, 2022 (the “ATM Program”), it has issued and completed sales of new ordinary shares (the “Ordinary Shares”) in